Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | ADA | P00813 | 7/20 | 0.36 |
| ▸ | PDE2A | O00408 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8219211 | 0.90 | NOS1 (0.38) | ADORA2AADORA1ADACYP3A4CYP1A2 | |
| SCHEMBL6036797 | 0.85 | CDK1 (0.34) | ADORA2AADORA1ADAPDE2ACYP3A4 | |
| Trifluoroacetic Acid SCHEMBL6509649 | 0.78 | S1PR1 (0.37) | LMNA | |
| SCHEMBL6267281 | 0.77 | USP2 (0.30) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL18546888 | 0.77 | CDK1 (0.34) | ADAPDE2ACYP3A4PDE4APDE4B | |
| SCHEMBL10438293 | 0.75 | POLA1 (0.35) | CDK1CCNB1 | |
| SCHEMBL67129 | 0.75 | CDK1 (0.31) | CDK1CCNB1 | |
| SCHEMBL6009519 | 0.74 | ADORA2A (0.38) | ADORA2AADORA1KDM4EALDH1A1CDK1 | |
| SCHEMBL4551801 | 0.73 | ADORA2A (0.44) | ADORA2AADORA1CDK1CCNB1 | |
| SCHEMBL16146635 | 0.73 | XDH (0.42) | ADORA2AADORA1CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 332 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059301-A1 | Fusion Protein Construct | NORTHWESTERN UNIVERSITY | 2025-02-20 | — | — | US | claimed |
| CN-108774232-B | 2, 3-dihydroimidazo [1,2-c ] quinazoline substituted derivatives | 拜耳知识产权有限责任公司 | 2022-08-09 | — | — | CN | claimed |
| CN-107872977-B | Combination of an IRAK4 inhibitor and a BTK inhibitor | 拜耳制药股份公司 | 2021-07-09 | — | — | CN | claimed |
| US-20190161556-A1 | Fusion Protein Construct | NORTHWESTERN UNIVERSITY | 2019-05-30 | — | — | US | claimed |
| CN-109661407-A | Fusion protein constructs | 西北大学 | 2019-04-19 | — | — | CN | claimed |
| EP-3464384-A1 | FUSION PROTEIN CONSTRUCT | Northwestern University (US) | 2019-04-10 | — | — | EP | claimed |
| US-9890147-B2 | 2,3-benzodiazepines | BAYER PHARMA AKTIENGESELLSHAFT (DE) | 2018-02-13 | — | — | US | claimed |
| WO-2017214151-A1 | FUSION PROTEIN CONSTRUCT | NORTHWESTERN UNIVERSITY (US) | 2017-12-14 | — | — | WO | claimed |
| US-9663523-B2 | BET protein-inhibiting 5-aryltriazoleazepines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-05-30 | — | — | US | claimed |
| US-9278925-B2 | Substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-03-08 | — | — | US | claimed |
| WO-2008070150-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-12 | — | — | WO | claimed |
| WO-2007000234-A1 | MOXIFLOXACIN THERAPEUTIC USE FOR TREATING IMMUNE SYSTEM FUNCTIONAL DISTURBANCES | BAYER HEALTHCARE AG (DE) | 2007-01-04 | — | — | WO | claimed |
| EP-1370211-A4 | CO-ADMINISTRATION OF MELANOCORTIN RECEPTOR AGONIST AND PHOSPHODIESTERASE INHIBITOR FOR TREATMENT OF CYCLIC-AMP ASSOCIATED DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2005-02-09 | — | — | EP | claimed |
| EP-1370211-A2 | CO-ADMINISTRATION OF MELANOCORTIN RECEPTOR AGONIST AND PHOSPHODIESTERASE INHIBITOR FOR TREATMENT OF CYCLIC-AMP ASSOCIATED DISORDERS | Bristol-Myers Squibb Company (US) | 2003-12-17 | — | — | EP | claimed |
| US-20030069169-A1 | Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-10 | — | — | US | claimed |
| WO-2002069905-A2 | CO-ADMINISTRATION OF MELANOCORTIN RECEPTOR AGONIST AND PHOSPHODIESTERASE INHIBITOR FOR TREATMENT OF CYCLIC-AMP ASSOCIATED DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-09-12 | — | — | WO | claimed |
| EP-0871449-A1 | HYDROXYNONYLADENINE ANALOGS WITH ENHANCED LIPOPHILIC AND ANTI-ISCHEMIC TRAITS | Cypros Pharmaceutical Corporation (US) | 1998-10-21 | — | — | EP | claimed |
| EP-0871449-A4 | — | — | 1998-10-21 | — | — | EP | claimed |
| WO-1997028803-A1 | HYDROXYNONYLADENINE ANALOGS WITH ENHANCED LIPOPHILIC AND ANTI-ISCHEMIC TRAITS | CYPROS PHARMACEUTICAL CORPORATION (US) | 1997-08-14 | — | — | WO | claimed |
| US-5491146-A | ADENOSIN DEAMINASE INHIBITORS | CYPROS PHARMACEUTICAL CORPORATION (US) | 1996-02-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069169-A1 | Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders | MC4R, MC3R, MC1R | ADORA2A 28/4885ADORA1 41/4885ADA 896/4885 |
| US-20250059301-A1 | Fusion Protein Construct | RPS27A, CD2BP2, JMJD7 | ADORA2A 4396/4885ADORA1 4672/4885ADA 158/4885 |
| US-20190161556-A1 | Fusion Protein Construct | RPS27A, CD2BP2, JMJD7 | ADORA2A 4396/4885ADORA1 4672/4885ADA 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.